Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

por Verstovsek, Srdan, Odenike, Olatoyosi, Singer, Jack W., Granston, Tanya, Al-Fayoumi, Suliman, Deeg, H. Joachim
Publicado 2016